alovudine has been researched along with Osteosarcoma in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bradshaw, TJ; Forrest, LJ; Jallow, N; Jeraj, R; Yip, S | 1 |
Boerman, OC; Fleuren, ED; Flucke, UE; Franssen, GM; Houghton, PJ; Oyen, WJ; Roeffen, MH; van der Graaf, WT; Versleijen-Jonkers, YM | 1 |
Benz, MR; Czernin, J; Eilber, FC; Federman, N; Tap, WD; Tchekmedyian, N | 1 |
1 review(s) available for alovudine and Osteosarcoma
Article | Year |
---|---|
Utilization of positron emission tomography in the management of patients with sarcoma.
Topics: Bone Neoplasms; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Osteosarcoma; Positron-Emission Tomography; Radiopharmaceuticals; Sarcoma | 2009 |
2 other study(ies) available for alovudine and Osteosarcoma
Article | Year |
---|---|
Spatiotemporal stability of Cu-ATSM and FLT positron emission tomography distributions during radiation therapy.
Topics: Adenocarcinoma; Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Proliferation; Chondrosarcoma; Coordination Complexes; Dideoxynucleosides; Dog Diseases; Dogs; Dose Fractionation, Radiation; Multimodal Imaging; Nose Neoplasms; Organometallic Compounds; Osteosarcoma; Paranasal Sinus Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Thiosemicarbazones; Tomography, X-Ray Computed | 2014 |
Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Cell Line, Tumor; Cisplatin; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Osteosarcoma; Positron-Emission Tomography; Protein Kinase Inhibitors; Sirolimus; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |